Michele Bronson

2.9k total citations · 1 hit paper
9 papers, 869 citations indexed

About

Michele Bronson is a scholar working on Psychiatry and Mental health, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Michele Bronson has authored 9 papers receiving a total of 869 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Psychiatry and Mental health, 3 papers in Cardiology and Cardiovascular Medicine and 3 papers in Oncology. Recurrent topics in Michele Bronson's work include Migraine and Headache Studies (4 papers), Peptidase Inhibition and Analysis (3 papers) and Blood Coagulation and Thrombosis Mechanisms (3 papers). Michele Bronson is often cited by papers focused on Migraine and Headache Studies (4 papers), Peptidase Inhibition and Analysis (3 papers) and Blood Coagulation and Thrombosis Mechanisms (3 papers). Michele Bronson collaborates with scholars based in United States, Canada and Australia. Michele Bronson's co-authors include John T. Curnutte, Mark Crowther, Pamela B. Conley, Genmin Lu, Deborah Siegal, Brian L. Wiens, Stuart J. Connolly, Janet M. Leeds, Alex Gold and Janice Castillo and has published in prestigious journals such as New England Journal of Medicine, Neurology and European Heart Journal.

In The Last Decade

Michele Bronson

9 papers receiving 841 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

2015 732 citations Deborah Siegal, John T. Curnutte et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Michele Bronson

Since Specialization

Citations

This map shows the geographic impact of Michele Bronson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele Bronson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele Bronson more than expected).

Fields of papers citing papers by Michele Bronson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele Bronson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele Bronson. The network helps show where Michele Bronson may publish in the future.

Co-authorship network of co-authors of Michele Bronson

This figure shows the co-authorship network connecting the top 25 collaborators of Michele Bronson. A scholar is included among the top collaborators of Michele Bronson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele Bronson. Michele Bronson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY VOLUNTEERS OF VENT-03, A NOVEL CGAS INHIBITOR FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS 2025 ·The Journal of Rheumatology ·Xavier Valencia, Kelly A. Pike, (unknown), Conrad Winters, Jeanne W. Stewart, Michele Bronson, Ramsay E. Beveridge, (unknown), (unknown), (unknown), Ofer Spiegelstein	1
2	Reversal of Apixaban and Rivaroxaban Anticoagulation by Andexanet Alfa in ANNEXA-A and ANNEXA-R as Assessed by Non-Tissue Factor-Initiated Thrombin Generation Independent of Tissue Factor Pathway Inhibitor 2018 ·Genmin Lu, (unknown), Michele Bronson, Mark Crowther, Pamela B. Conley, John T. Curnutte	2
3	5069Reversal of apixaban and rivaroxaban anticoagulation by andexanet alfa in ANNEXA-A&R as assessed by non-tissue factor (TF)-initiated thrombin generation independent of TF pathway inhibitor (TFPI) 2018 ·European Heart Journal ·Genmin Lu, (unknown), Michele Bronson, Mark Crowther, Pamela B. Conley, J T Curnutte	2
4	Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity breakdown → 2015 ·New England Journal of Medicine ·Deborah Siegal, John T. Curnutte, Stuart J. Connolly, Genmin Lu, Pamela B. Conley, Brian L. Wiens, Vandana Mathur, Janice Castillo, Michele Bronson, Janet M. Leeds, (unknown), Alex Gold, Mark Crowther	732
5	Cardiovascular and Hemodynamic Parameters in Women Following IV Administration of LBR-101, a Monoclonal Antibody Against CGRP (P7.198) 2014 ·Neurology ·Marcelo E. Bigal, (unknown), Michele Bronson, Sarah Walter, Rafael Escandón	1
6	Assessment of Cardiovascular Safety in Cynomolgus Monkeys Following IV Administration of LBR-101 (P7.175) 2014 ·Neurology ·Sarah Walter, Michele Bronson, Marcelo E. Bigal	1
7	Safety and Tolerability of LBR-101, a Humanized Monoclonal Antibody That Blocks the Binding of CGRP to Its Receptor - Results of the Phase 1 Program (P7.190) 2014 ·Neurology ·Rafael Escandón, Michele Bronson, Sarah Walter, Marcelo E. Bigal	1
8	Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP 2014 ·Cephalalgia ·Marcelo E. Bigal, Sarah Walter, Michele Bronson, (unknown), Rafael Escandón	53
9	Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program 2013 ·Cephalalgia ·Marcelo E. Bigal, Rafael Escandón, Michele Bronson, Sarah Walter, (unknown), John P. Huggins, Pamela D. Garzone	76

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact